UNITED STATES DISTRICT COURT MIDDLE DISTRICT OF TENNESSEE NORTHEASTERN DIVISION

UNITED STATES OF AMERICA)	
)	
V.) Case No. 2:21-CR-	00008
[1] THOMAS K. WEIR) Case No. 2.21-CR	-00008
) JUDGE TRAUGE	R
[2] CHARLES R. OAKLEY)	
[3] WILLIAM L. DONALDSON)	
[4] DAMELA CDIVEV		
[4] PAMELA SPIVEY)	

UNITED STATES' EXHIBIT LIST

The United States, by and through Assistant United States Attorneys Sarah K. Bogni and Nani M. Gilkerson, hereby submits the following Exhibit List for the jury trial in the above-referenced case, set for November 28, 2023. Electronic copies of the proposed exhibits have been provided to defendants contemporaneously with this filing. To date, the United States has not received reciprocal discovery from defendants, nor can it fully anticipate the defenses to be presented at trial. As such, the United States requests leave to amend and supplement the following exhibit list should other exhibits be deemed necessary in advance of trial, or should certain evidence become relevant during the course of trial.

EXHIBIT NUMBER	DESCRIPTION	BATES NUMBER
1	911 call - audio file (DISC)	USAO-JP-001329
2	CAD reports (ID ONLY)	USAO-JP-003051
3	Bodycam footage: 4/19/2016 (file: tom weir 4-19-16.mov] (DISC)	US-000350
4	Bodycam footage: 6/22/2016 (file: 20160622_0002 Dal Hollow Pharmacy.mov] (DISC)	US-000350
5	Bodycam footage: 6/22/2016 (file: 20160622_0003 Tom Weir.mov] (DISC)	US-000350
6	Bodycam footage: 11/18/2016 (file: 20161118_0011 Bill Donaldson.mov] (DISC)	US-000350
7	Bodycam footage: 11/18/2016 (file: 19700612_0171 Bill Donaldson.mov] (DISC)	US-000350
8	Bodycam footage: 11/18/2016 (file: 20161118_0012 Bill Donaldson.mov] (DISC)	US-000350
9	Bodycam footage: 11/18/2016 (file: 20161118_0013 Bill Donaldson.mov] (DSIC)	US-000350
10	Bodycam footage: 11/18/2016 (file: 20161118_0014 Bill Donaldson.mov] (DISC)	US-000350
11	Aerial TBI photos	US-003143-3152
12	Photo - Dale Hollow Pharmacy outside	US-003153
13	Photo - Dale Hollow Pharmacy drive thru	US-003154
14	Photo - Dale Hollow Pharmacy handwritten notes posted on wall	DOJ-DH-043548
15	Photo - Dale Hollow Pharmacy behind counter	DOJ-DH-043552
16	Photo - Dale Hollow Pharmacy behind counter	DOJ-DH-043553
17	Photo - Dale Hollow Pharmacy counter	DOJ-DH-043554
18	Photo - Dale Hollow Pharmacy medication shelves/drive thru	DOJ-DH-043555
19	Photo - Dale Hollow Pharmacy behind counter	DOJ-DH-043556
20	Photo - Xpress Pharmacy outside	USAO-JP-003054
21	Photo - Xpress Pharmacy outside	USAO-JP-003058
22	Photo - Xpress Pharmacy outside sign	USAO-JP-003061
23	Photo - Xpress Pharmacy outside building side	USAO-JP-003063
24	Photo - Xpress Pharmacy drive thru window	USAO-JP-003074
25	Photo - Xpress Pharmacy drop off/pick up sign	USAO-JP-003085
26	Photo - Xpress Pharmacy	USAO-JP-003086
27	Photo - Xpress Pharmacy inside facing outside window	USAO-JP-003096
28	Photo - Xpress Pharmacy medication shelves	USAO-JP-003100
29	Photo - Xpress Pharmacy medication shelves	USAO-JP-003106
30	Photo - Xpress Pharmacy medication shelves and safes	USAO-JP-003108
31	Photo - Xpress Pharmacy safes	USAO-JP-003122
32	Photo - Xpress Pharmacy inside safe	USAO-JP-003125
33	Photo - Xpress Pharmacy sink area	USAO-JP-003142
34	Photo - Xpress Pharmacy desk area	USAO-JP-003149
35	Photo - Xpress Pharmacy fax machine/telephone	USAO-JP-003153
36	Photo - Xpress Pharmacy file holders	USAO-JP-003154
37	Photo - Xpress Pharmacy file holder	USAO-JP-003161
38	Photo - Xpress Pharmacy store area	USAO-JP-003213
	1 2	

39	Photo - Xpress Pharmacy desk area	USAO-JP-003217
40	Photo - Xpress Pharmacy store area	USAO-JP-003221
41	Photo - Xpress Pharmacy computer monitor with TN CSMD on screen	USAO-JP-003259
42	Photo - Xpress Pharmacy wall signs re doctor shopping and TennCare fraud	USAO-JP-003599
43	Photo - Xpress Pharmacy Certificate of Completion (Pamela Spivey)	USAO-JP-003602
44	Photo - Xpress Pharmacy State of TN Home Medical Equipment License	USAO-JP-003605
45	Photo - Xpress Pharmacy TN BOP Pharmacy License	USAO-JP-003612
46	Photo - Xpress Pharmacy DEA Controlled Substance Registration Certificate	USAO-JP-003616
47	Photo - Pharmacy Technician Certification Board CPhT certificate (Pamela Spivey)	USAO-JP-003619
48	Photo - Xpress store area/recliner chairs	USAO-JP-003626
49	Participating Pharmacy Agreement - Magellan and Dale Hollow Pharmacy 5/21/2013	USAO-JP-002101
50	TennCare Participating Pharmacy Application - Magellan and Dale Hollow Pharmacy 6/24/2016	USAO-JP-002102
51	Pharmacy Network Provider Agreement - Magellan and Dale Hollow Pharmacy 12/12/2018	USAO-JP-002104
52	Participating Pharmacy Agreement - Magellan and Xpress Pharmacy 4/5/2013	USAO-JP-002412
53	TennCare Participating Pharmacy Application - Magellan and Xpress Pharmacy 5/11/2016	USAO-JP-002413
54	Record certification - Magellan	US-003141
55	Pharmacy Network Provider Agreement - Magellan and Xpress Pharmacy 12/12/2018	CCX_00027329
56	PharmacyRx Application Service Provider Agreement - McKesson and Dale Hollow Pharmacy 3/25/2015	USAO-JP-001909
57	Record certification	US-002849
58	Caremark Provider Agreement - CVS and Xpress Pharmacy 6/21/2011	US-000001
59	Caremark Provider Agreement - CVS and Dale Hollow Pharmacy 9/24/2012	US-000005
60	Record certification - CVS	US-002846
61	Pharmacy Provider Agreement - Express Scripts and Dale Hollow Pharmacy 12/21/2007	US-002758
62	Amended and Restated PSAO Services Agreement - Express Scripts and Strategic Health Alliance II, dba Accesshealth 11/26/2013	US-002777
63	Record certification - Express Scripts	US-002816
64	Pharmacy Provider Agreement - Express Scripts and Dale Hollow Pharmacy 1/24/2014	US-000127
65	Pharmacy Provider Agreement - Express Scripts and Xpress Pharmacy 6/2/2014	US-000147
66	Amended and Restated PSAO Services Agreement - Express Scripts and Amerisource Bergen 11/1/2013	US-000036
67	Amended and Restated PSAO Services Agreement - Express Scripts and American Associated Druggists, Inc dba United Drugs 10/4/2013	US-000082
68	Amended and Restated PSAO Services Agreement - Express Scripts and American Pharmacy Network Solutions, LLC 7/12/2013	US-000104
69	Business record affidavit - Express Scripts	US-002847
70	Pharmacy Provider Agreement and Amendments- Humana and Xpress Pharmacy 6/28/2011	US-000178
71	Pharmacy Provider Agreement and Amendments- Humana and Dale Hollow Pharmacy 6/14/2011	US-000261

72	Record certification - Humana	US-002848
73	Medicare Part D Pharmacy Network Agreement - Aetna and Xpress Pharmacy 11/24/2015	Clay-AIW-0000389713
74	Dale Hollow Pharmacy and American Pharmacy Network Solutions 2/22/2016	DOJ-DH-00044311
75-76	INTENTIONALLY LEFT BLANK	
77	TN Department of Health letter verification of Xpress Pharmacy 6/22/2018	CCX_00027315
78	Dale Hollow Pharmacy - controlled substances registration	USAO-JP-002102.25
79	Xpress Pharmacy - controlled substances registration	USAO-JP-002413.11
80	DEA certified registration - Dale Hollow Pharmacy	USAO-JP-005193
81	DEA certified registration – Xpress Pharmacy	USAO-JP-005191
82	Certified copy of Oakley Pharmacy, Inc. records	USAO-JP-005154
83	Certified copy of Xpress Pharmacy records	USAO-JP-005155
84	Certified copy of Donaldson Pharmacy records	US-003248
85	Oakley Pharmacy - wage reports and certification	US-003643
86	Xpress Pharmacy - wage reports and certification	US-003657
87	Warranty Deed - 43 Weir Lane, Celina, TN 38551 (4/8/2014)	USAO-JP-005188
88	Warranty Deed - 49 Weir Ln, Celina, TN 38551 (11/30/2017)	USAO-JP-005189
89	State of TN Real Estate Assessment Data 145 Donaldson Avenue 3/26/2019	USAO-JP-005190
90	2015 Kia Soul purchase records	USAO-JP-005161
91	Record certification - Hyundai	US-003639
92	2015 Kia Soul registration records with certification	USAO-JP-005162
93	Notice of Inspection of Controlled Premises - Dale Hollow Pharmacy (10/14/2016)	USAO-JP-002108.087
94	DEA-12 Receipt for Cash or Other Items - CFR documents (Dale Hollow Pharmacy 10/14/2016)	USAO-JP-002108.088
95	Emails between Samantha Rogers and Tom Weir regarding MOA (10/25, 10/26, 11/15/2016)	USAO-JP-002108.093
96	Email to Weir and Oakley from Samantha Rogers regarding MOA (11/29/2016)	USAO-JP-002108.094
97	Email to Weir and Oakley from Samantha Rogers regarding MOA (1/17/2017)	USAO-JP-002108.095
98	Email to Weir from Samantha Rogers regarding MOA (1/24/2017)	USAO-JP-002108.096
99	Email to Weir from Samantha Rogers regarding MOA (2/21/2017)	USAO-JP-002108.097
100	Email to Weir and Oakley from Samantha Rogers regarding MOA (3/2/2017)	USAO-JP-002108.098
101	DEA-12 Receipt for Cash or Other Items - CFR documents (Xpress Pharmacy 8/29/2018)	US-003194
102	Memorandum of Agreement - Dale Hollow Pharmacy 3/10/2017	USAO-JP-001232
103	Amerisource Bergen - Email regarding Griffith response and attached policies and procedures document (10/18/2016)	USAO-JP-001338.32
104	Amerisource Bergen - Email from Griffith to CSRA Customer Inquiry (1/31/2017)	USAO-JP-001345
105	Amerisource Bergen - Email from CSRA Customer Inquiry to Tom Weir re Xpress Pharmacy (1/31/2017)	USAO-JP-001349
106	Amerisource Bergen - Retail Pharmacy Questionnaire - Oakley Pharmacy	USAO-JP-002741.10
107	Amerisource Bergen - Retail Pharmacy Questionnaire - Xpress Pharmacy	USAP-JP-001335.02
108	Contract For Monitoring Services (Affiliated Monitors, Inc. and Dale Hollow Pharmacy 2/15/2016)	USAO-JP-002617
109	Affiliated Monitors, Inc, - First Monitoring Report	USAO-JP-002583

110	Affiliated Monitors, Inc, - Second Monitoring Report	USAO-JP-002605
111	Affiliated Monitors, Inc, - Third Monitoring Report	USAO-JP-002615
112	Affiliated Monitors, Inc, - Fourth Monitoring Report	USAO-JP-002625
113	Affiliated Monitors, Inc, - Fifth Monitoring Report	USAO-JP-002631
114	Affiliated Monitors, Inc, - Sixth Monitoring Report	USAO-JP-002635
115	Affiliated Monitors, Inc, - Seventh Monitoring Report	USAO-JP-002624
116	Affiliated Monitors, Inc, - Eight Monitoring Report	USAO-JP-002639
117	Affiliated Monitors, Inc, - Ninth Monitoring Report	USAO-JP-002591
118	Affiliated Monitors, Inc, - Tenth Monitoring Report	USAO-JP-002590
119	TN Board of Pharmacy Board Meeting 1/27-28/2015	USAO-JP-002628
120	Dale Hollow Pharmacy report 9/2/2016	USAO-JP-002626.02
121	Dale Hollow Pharmacy report 12/14/2016	USAO-JP-003898; USAO- JP-003961
122	Dale Hollow Pharmacy report 6/28/2017	USAO-JP-002632.02
123	Dale Hollow Pharmacy report 10/4/2017	USAO-JP-002634.02
124	Dale Hollow Pharmacy report 8/31/2018	USAO-JP-002588.03
125	Dale Hollow Pharmacy report 10/31/2018	USAO-JP-002592.02
126	Dale Hollow Healthmart report 1/24/2018	USAO-JP-002637.03
127	Dale Hollow Healthmart report 4/25/2018	USAO-JP-002641.03
128	Dale Hollow Pharmacy Plan of Action 11/7/2016	USAO-JP-003950
129	Email from Weir to Steve Nemmers re Consent Order (2/10/2016)	USAO-JP-003812
130	Email from Steve Nemmers to Weir re monitoring (2/22/2016)	USAO-JP-003826
131	Email from Wendy Anderson to Weir re date for monitoring visit (4/5/2016)	USAO-JP-003839
132	Email from Pam Spivey to Wendy Anderson re date for monitoring visit (4/5/2016)	USAO-JP-003840
133	Email from Cathy Cordy to Weir re quarterly report (7/12/2016)	USAO-JP-003849
134	Emails between Tommy Malone and Cathy Cordy re Dale Hollow Pharmacy (8/19/2016; 8/29/2016; 9/5/2016)	USAO-JP-003868
135	Emails between Cathy Cordy and Reginald Dilliard re Dale Hollow Pharmacy monitoring (9/19/2016)	USAO-JP-003876
136	Emails between Cathy Cordy and Tommy Malone re Dale Hollow Pharmacy (9/20/2016 and 9/21/2016)	USAO-JP-003877
137	Emails between Cathy Cordy and Reginald Dilliard and Tommy Malone re Dale Hollow Pharmacy monitoring (10/31/2016; 12/6/2016)	USAO-JP-003894
138	Emails between Tommy Malone and Cathy Cordy re Dale Hollow Pharmacy (12/28/2016; 1/1/2017; 1/2/2017)	USAO-JP-002645
139	Email from Cathy Cordy to Oakley re Quarterly Report (2/15/2017)	USAO-JP-002689
140	Email from Tommy Malone to Cathy Cordy re 4/14/2017 report [attached] (4/16/2017)	USAO-JP-003771
141	Email from Cathy Cordy to Oakley re Fourth Quarterly Report (5/5/2017)	USAO-JP-002647
142	Email from Tommy Malone to Cathy Cordy re quarterly report (2/23/2018)	USAO-JP-003778
143	Email from Cathy Cordy to Weir and Polston re Seventh Quarterly Report (2/26/2018)	USAO-JP-002666
144	Email from Tommy Malone to Cathy Cordy re Dale Hollow Pharmacy draft report (5/16/2018)	USAO-JP-004038
145	Emails between Tommy Malone and Cathy Cordy re Dale Hollow Pharmacy (8/22/2018 and 8/24/2018)	USAO-JP-002695
146	Record certification - Affiliated Monitors, Inc.	USAO-JP-002738
147	TN Board of Pharmacy Consent Order - Oakley Pharmacy 7/31/2014	Xpress-000025.04

148	TN Board of Pharmacy Agreed Order - Oakley Pharmacy 1/19/2016	Xpress-000031.149
149	TN Board of Pharmacy Consent Order - William Donaldson/Donaldson	Xpress-000031.147 Xpress-000034.63
149	Pharmacy 6/20/2008	Apress-000034.03
150	TN Board of Pharmacy Consent Order - William Donaldson 5/18/2011	Xpress-000034.73
151	TN Board of Pharmacy Consent Order - Michael Griffith 11/27/2011	Xpress-000026.69
152	TN Board of Pharmacy Consent Order for Reinstatement - Michael Griffith 4/11/2012	USAO-JP-001348
153	TN Board of Pharmacy Consent Order - John Polston 7/30/2015	Xpress-000026.53
154	TN Board of Pharmacy Consent Order - Brian Cole 7/30/2015	
155	TN Board of Pharmacy Consent Order - Larry Larkin 2/3/2004	
156	TN Board of Pharmacy Consent Order for Reinstatement - Larry Larkin 8/18/2006	
157	TN Board of Pharmacy Consent Order - Larry Larkin 12/6/2008	
158	TN Board of Pharmacy 2014001401 - Allegations Report - Complainant Pamela Spivey 7/9/2014	Xpress-000026.11
159	TN Board of Pharmacy 2014001401 - Letter of Warning to John Polston 4/2/2015	Xpress-000026.32
160	TN Board of Pharmacy Letter to Oakley Pharmacy re notice of facts/conduct 4/6/2015	Xpress-000026.43
161	INTENTIONALLY LEFT BLANK	
162	Affidavit of Bobby Oakley 7/16/2014	Xpress-000031.030
163	TN Board of Pharmacy Letter to Tom Weir from Stefan Cange re consent order correction 1/15/2016	Xpress-000031.144
164	INTENTIONALLY LEFT BLANK	
165	TN Board of Pharmacy Regulatory Letter to William Donaldson re dispensing 3/29/1993	Xpress-000034.51
166	TN Board of Pharmacy Notice of Hearing and Charges - Oakley Pharmacy, Inc. 10/14/2015	Xpress-00031.079-086
167	TN Board of Pharmacy Notice of Service - Oakley Pharmacy, Inc. 10/26/2015	Xpress-000031.073-075
168-174	INTENTIONALLY LEFT BLANK	
175	Scanned folder from Michael Griffith	CCX-00000004
176	Original RX30 hard drive (physical exhibit/ID ONLY)	Xpress-028477
177	RX30 – K.C. patient pharmacy profile	Xpress-000360-361
178	RX30 – P.P. patient pharmacy profile	Xpress-000405-406
179	McKesson – J.B. patient pharmacy profile	USAO-JP-005231.14
180	McKesson – J.H.S. patient pharmacy profile	USAO-JP-005231.13
181	McKesson – B.S. patient pharmacy profile	USAO-JP-005231.05
182	McKesson – R.T. patient pharmacy profile	USAO-JP-005231.24
183	McKesson – J.T. patient pharmacy profile	USAO-JP-005231.12
184	McKesson – J.A. patient pharmacy profile	USAO-JP-005231.11
185	McKesson – J.L. patient pharmacy profile	USAO-JP-005231.17
186	McKesson – K.H. patient pharmacy profile	USAO-JP-005231.19
187	Certificate of Records Custodian - McKesson	US-003142
188	CGS - EFT Authorization Agreement - Oakley Pharmacy 9/27/2017	US-000351
189	CGS - EFT Authorization Agreement - Xpress Pharmacy 11/24/2011	US-000358
190	Affidavit - CGS Administrators, LLC	US-000366
191	NGS - EDI Enrollment Agreement - Xpress Pharmacy 2/27/2012	US-000367
192	NGS - CEDI Supplier Authorization Form - Oakley Pharmacy 1/9/2018	US-000383

193 Certification of Domestic Records - National Government Services			
Pharmacy NFEAST - COI ADR CMS-855S Medicare Enrollment Application Xpress Dis-000724	193		
NPEAST - COLADR CMS-855S Medicare Enrollment Application Xpress Pharmacy 16/2016	194		US-000696
NPEAST - COI ADR CMS-855S Medicare Enrollment Application Xpress Dis-000847	195	NPEAST - COI ADR CMS-855S Medicare Enrollment Application Xpress	US-000724
197 NPEAST - CMS Certification Statement for DMEPOS Supplier Xpress DS-000879 Pharmacy 1/9/2017 NPEAST - Licenses US-000894 US-000894 199 NPEAST - COLADR CMS-855S Medicare Enrollment Application Xpress DS-000933 Pharmacy 3/07/2017 US-000935 US-000935 200 NPEAST - COLADR Enrollment Application Xpress Pharmacy 8/9/2017 US-000935 US-000942 Pharmacy 3/07/2017 US-000942 Pharmacy 3/07/2017 US-000998 US-000942 Pharmacy 3/07/2017 US-000998 US-001081 US-001082	196	NPEAST - COI ADR CMS-855S Medicare Enrollment Application Xpress	US-000847
198 NPEAST - Licenses US-000894 199 NPEAST - COL ADR CMS-855S Medicare Enrollment Application Xpress Pharmacy 3/20/2017 200 NPEAST - COL ADR Enrollment Application Xpress Pharmacy 8/9/2017 201 NPEAST - Medicare Participating Physician or Supplier Agreement Xpress 202 NPEAST - Medicare Participating Physician or Supplier Agreement Xpress 203 NPEAST - Certification Statement from application 11/24/2011 204 NPEAST - Certification Statement from application 11/24/2011 205 NPEAST - Certification Statement from application 11/24/2011 206 NPEAST - Certification Statement from application 12/15/2011 207 US-001027 208 NPEAST - Certification Statement from application of All Pharmacy 209 NPEAST - Reply to Letter to Oakley Pharmacy re Medicare application 201 NPEAST - Reply to Letter to Oakley Pharmacy re Medicare application 202 202 PGBA - FET Authorization Agreement - Oakley Pharmacy 208 Business Record Affidavit - Novitas Solutions 209 PGBA - EFT Authorization Agreement - Oakley Pharmacy 210 PGBA - CMS-855B Medicare Enrollment Application - Oakley Pharmacy 211 PGBA - CMS-855B Medicare Enrollment Application - Oakley Pharmacy 212 PGBA - Letter to Oakley Pharmacy re Medicare application 8/25/2015 213 Business Record Affidavit - Palmetto GBA (DH) 214 Business Record Affidavit - Palmetto GBA (DH) 215 Business Record Affidavit - Palmetto GBA (DH) 216 Declaration of Carl Gainor 2/5/2019 217 Addendum to Declaration of Carl Gainor 3/30/2023 218 Pharmacist Review on Oakley Pharmacy 228 Declaration of Carl Gainor 2/5/2019 229 Overview of Dale Hollow Pharmacy Narrase Pharmacy, and Anderson 220 Pharmacist Review on Apress Pharmacy 2/28/2019 221 FDA Drug Safety Communications re warning about risks and death with combos 8/31/2016 (demonstrative exhibit) 222 T.C.A. § 53-1-101 - Administration short title 223 T.C.A. § 53-1-108 - Prescriptions 10/1	197	NPEAST - CMS Certification Statement for DMEPOS Supplier Xpress	US-000879
Pharmacy 3/20/2017	198		US-000894
200 NPEAST - COI ADR Enrollment Application Xpress Pharmacy 8/9/2017 US-000935 201 NPEAST - Medicare Participating Physician or Supplier Agreement Xpress Pharmacy US-000942 202 NPEAST - COI ADR Enrollment Application Xpress Pharmacy 1/9/2017 US-000998 203 NPEAST - COI ADR Enrollment Application Xpress Pharmacy 1/9/2017 US-001081 204 NPEAST - Certification Statement from application 11/24/2011 US-001027 205 NPEAST - CMS-855S Medicare Enrollment Application Oakley Pharmacy 4/17/2017 US-001139 206 NPEAST - Letter to Oakley Pharmacy re Medicare application 9/25/2017 US-001263 207 NPEAST - Reply to Letter to Oakley Pharmacy re Medicare application 9/27/2017 US-001271 208 Business Record Affidavit - Novitas Solutions US-001328 209 PGBA - EFT Authorization Agreement - Oakley Pharmacy 6/8/2011 US-001482 210 PGBA - CMS-855B Medicare Enrollment Application - Oakley Pharmacy 8/8/2011 US-001482 211 PGBA - CMS-855B Medicare Enrollment Application - Oakley Pharmacy 4/1/2015 US-001480 212 PGBA - Letter to Oakley Pharmacy re Medicare application 8/25/2015 US-001430 212 PGBA - Letter to Oakley Ph	199		US-000933
NPEAST - Medicare Participating Physician or Supplier Agreement Xpress Pharmacy Pharmacy Pharmacy NPEAST - COI ADR Enrollment Application Xpress Pharmacy 1/9/2017	200		US-000935
202 NPEAST - COI ADR Enrollment Application Xpress Pharmacy 1/9/2017 US-000998	201	NPEAST - Medicare Participating Physician or Supplier Agreement Xpress	US-000942
NPEAST - Certification Statement from application 11/24/2011	202		US-000998
NPEAST - Certification Statement from application 12/15/2011	203		US-001081
NPEAST - CMS-855S Medicare Enrollment Application Oakley Pharmacy 4/17/2017 US-001263		**	
NPEAST - Letter to Oakley Pharmacy re Medicare application 9/25/2017 US-001263		NPEAST - CMS-855S Medicare Enrollment Application Oakley Pharmacy	
207 NPEAST - Reply to Letter to Oakley Pharmacy re Medicare application 9/27/2017 9/27/2017 US-001328 208 Business Record Affidavit - Novitas Solutions US-001328 209 PGBA - EFT Authorization Agreement - Oakley Pharmacy 6/8/2011 US-001482 210 PGBA - CMS-855B Medicare Enrollment Application - Oakley Pharmacy 8/8/2011 w/certification 211 PGBA - CMS-855B Medicare Enrollment Application - Oakley Pharmacy 4/1/2015 US-001430 4/1/2015 US-001430 US-001441 212 PGBA - Letter to Oakley Pharmacy re Medicare application 8/25/2015 US-001471 213 Business Record Affidavit - Palmetto GBA (DH) US-001487 214 Business Record Affidavit - Palmetto GBA (DH) US-001489 215 Business Record Affidavit - Palmetto GBA (EFT - DH) US-001490 216 Declaration of Carl Gainor 2/5/2019 USAO-JP-001885 217 Addendum to Declaration of Carl Gainor 3/30/2023 218 Pharmacist Review on Oakley Pharmacy Inc. 2/28/2019 USAO-JP-005165 219 Pharmacist Review on Xpress Pharmacy 2/28/2019 USAO-JP-005172 220 Overview of Dale Hollow Pharmacy, Xpress Pharmacy, and Anderson Pharmacy 2/28/2019 USAO-JP-005166 221 FDA Drug Safety Communications re warning about risks and death with combos 8/31/2016 (demonstrative exhibit) 222 T.C.A. § 53-11-303 - Factors considered scope 223 T.C.A. § 53-11-303 - Prescriptions 10/1/2018-12/31/2018 224 T.C.A. § 53-11-308 - Prescriptions 7/1/2018-12/31/2018 225 T.C.A. § 53-11-311 - Buprenorphine; prescription requirements; exceptions 7/1/2015-4/11/2018 226 T.C.A. § 53-11-311 - Buprenorphine; prescription requirements; exceptions 7/1/2015-4/11/2018 227 T.C.A. § 53-11-311 - Buprenorphine; prescription requirements; exceptions 7/1/2015-4/11/2018 228 T.C.A. § 53-11-311 - Buprenorphine; prescription requirements; exceptions 7/1/2015-4/11/2018	206		US-001263
PGBA - EFT Authorization Agreement - Oakley Pharmacy 6/8/2011 US-001482	207	NPEAST - Reply to Letter to Oakley Pharmacy re Medicare application	US-001271
210 PGBA - CMS-855B Medicare Enrollment Application - Oakley Pharmacy 8/8/2011 w/certification 211 PGBA - CMS-855B Medicare Enrollment Application - Oakley Pharmacy 4/1/2015 212 PGBA - Letter to Oakley Pharmacy re Medicare application 8/25/2015 213 Business Record Affidavit - Palmetto GBA (DH) 214 Business Record Affidavit - Palmetto GBA (DH) 215 Business Record Affidavit - Palmetto GBA (DH) 216 Declaration of Carl Gainor 2/5/2019 217 Addendum to Declaration of Carl Gainor 3/30/2023 218 Pharmacist Review on Oakley Pharmacy 1nc. 2/28/2019 219 Pharmacist Review on Xpress Pharmacy 2/28/2019 220 Overview of Dale Hollow Pharmacy, Xpress Pharmacy, and Anderson Pharmacy 2/28/2019 221 FDA Drug Safety Communications re warning about risks and death with combos 8/3/1/2016 (demonstrative exhibit) 222 T.C.A. § 53-11-101 - Administration short title 223 T.C.A. § 53-11-303 - Factors considered scope 224 T.C.A. § 53-11-308 - Prescriptions 10/1/2013-6/30/2018 225 T.C.A. § 53-11-308 - Prescriptions 7/1/2018-12/31/2018 226 T.C.A. § 53-11-311 - Buprenorphine; prescription requirements; exceptions 7/1/2015-4/11/2018 228 T.C.A. § 53-11-311 - Buprenorphine; prescription requirements; exceptions 7/1/2015-4/11/2018	208	Business Record Affidavit - Novitas Solutions	US-001328
8/8/2011 w/certification 211 PGBA - CMS-855B Medicare Enrollment Application - Oakley Pharmacy 4/1/2015 212 PGBA - Letter to Oakley Pharmacy re Medicare application 8/25/2015 213 Business Record Affidavit - Palmetto GBA (DH) 214 Business Record Affidavit - Palmetto GBA (DH) 215 Business Record Affidavit - Palmetto GBA (EFT - DH) 216 Declaration of Carl Gainor 2/5/2019 217 Addendum to Declaration of Carl Gainor 3/30/2023 218 Pharmacist Review on Oakley Pharmacy Inc. 2/28/2019 219 Pharmacist Review on Xpress Pharmacy 2/28/2019 220 Overview of Dale Hollow Pharmacy, Xpress Pharmacy, and Anderson Pharmacy 2/28/2019 221 FDA Drug Safety Communications re warning about risks and death with combos 8/31/2016 (demonstrative exhibit) 222 T.C.A. § 53-1-101 - Administration short title 223 T.C.A. § 53-11-303 - Factors considered scope 224 T.C.A. § 53-11-308 - Prescriptions 10/1/2013-6/30/2018 225 T.C.A. § 53-11-308 - Prescriptions 7/1/2018-12/31/2018 227 T.C.A. § 53-11-311 - Buprenorphine; prescription requirements; exceptions 7/1/2015-4/11/2018 228 T.C.A. § 53-11-311 - Buprenorphine; prescription requirements; exceptions	209	PGBA - EFT Authorization Agreement - Oakley Pharmacy 6/8/2011	US-001482
211 PGBA - CMS-855B Medicare Enrollment Application - Oakley Pharmacy 4/1/2015 212 PGBA - Letter to Oakley Pharmacy re Medicare application 8/25/2015 213 Business Record Affidavit - Palmetto GBA (DH) 214 Business Record Affidavit - Palmetto GBA (DH) 215 Business Record Affidavit - Palmetto GBA (EFT - DH) 216 Declaration of Carl Gainor 2/5/2019 217 Addendum to Declaration of Carl Gainor 3/30/2023 218 Pharmacist Review on Oakley Pharmacy Inc. 2/28/2019 219 Pharmacist Review on Oakley Pharmacy 2/28/2019 220 Overview of Dale Hollow Pharmacy, Xpress Pharmacy, and Anderson Pharmacy 2/28/2019 221 FDA Drug Safety Communications re warning about risks and death with combos 8/31/2016 (demonstrative exhibit) 222 T.C.A. § 53-1-101 - Administration short title 223 T.C.A. § 53-11-303 - Factors considered scope 224 T.C.A. § 53-11-308 - Prescriptions 10/1/2013-6/30/2018 225 T.C.A. § 53-11-308 - Prescriptions 7/1/2018-12/31/2018 226 T.C.A. § 53-11-311 - Buprenorphine; prescription requirements; exceptions 7/1/2015-4/11/2018 228 T.C.A. § 53-11-311 - Buprenorphine; prescription requirements; exceptions	210		US-003227; US-003638
Business Record Affidavit - Palmetto GBA (DH) US-001487 214 Business Record Affidavit - Palmetto GBA (DH) US-001489 215 Business Record Affidavit - Palmetto GBA (EFT - DH) US-001490 216 Declaration of Carl Gainor 2/5/2019 USAO-JP-001885 217 Addendum to Declaration of Carl Gainor 3/30/2023 218 Pharmacist Review on Oakley Pharmacy Inc. 2/28/2019 USAO-JP-005165 219 Pharmacist Review on Xpress Pharmacy 2/28/2019 USAO-JP-005172 220 Overview of Dale Hollow Pharmacy, Xpress Pharmacy, and Anderson Pharmacy 2/28/2019 221 FDA Drug Safety Communications re warning about risks and death with combos 8/31/2016 (demonstrative exhibit) 222 T.C.A. § 53-1-101 - Administration short title 223 T.C.A. § 53-10-110 - Professional judgment of pharmacists' prevention of drug abuse; penalty 224 T.C.A. § 53-11-303 - Factors considered scope 225 T.C.A. § 53-11-308 - Prescriptions 10/1/2013-6/30/2018 226 T.C.A. § 53-11-311 - Buprenorphine; prescription requirements; exceptions 7/1/2015-4/11/2018 228 T.C.A. § 53-11-311 - Buprenorphine; prescription requirements; exceptions	211	PGBA - CMS-855B Medicare Enrollment Application - Oakley Pharmacy	US-001430
Business Record Affidavit - Palmetto GBA (DH) US-001489 215 Business Record Affidavit - Palmetto GBA (EFT - DH) US-001490 216 Declaration of Carl Gainor 2/5/2019 USAO-JP-001885 217 Addendum to Declaration of Carl Gainor 3/30/2023 218 Pharmacist Review on Oakley Pharmacy Inc. 2/28/2019 USAO-JP-005165 219 Pharmacist Review on Xpress Pharmacy 2/28/2019 USAO-JP-005172 220 Overview of Dale Hollow Pharmacy, Xpress Pharmacy, and Anderson Pharmacy 2/28/2019 221 FDA Drug Safety Communications re warning about risks and death with combos 8/31/2016 (demonstrative exhibit) 222 T.C.A. § 53-1-101 - Administration short title 223 T.C.A. § 53-10-110 - Professional judgment of pharmacists' prevention of drug abuse; penalty 224 T.C.A. § 53-11-303 - Factors considered scope 225 T.C.A. § 53-11-308 - Prescriptions 10/1/2013-6/30/2018 226 T.C.A. § 53-11-311 - Buprenorphine; prescription requirements; exceptions 7/1/2015-4/11/2018 228 T.C.A. § 53-11-311 - Buprenorphine; prescription requirements; exceptions	212	PGBA - Letter to Oakley Pharmacy re Medicare application 8/25/2015	US-001471
215 Business Record Affidavit - Palmetto GBA (EFT - DH) 216 Declaration of Carl Gainor 2/5/2019 217 Addendum to Declaration of Carl Gainor 3/30/2023 218 Pharmacist Review on Oakley Pharmacy Inc. 2/28/2019 219 Pharmacist Review on Xpress Pharmacy 2/28/2019 220 Overview of Dale Hollow Pharmacy, Xpress Pharmacy, and Anderson Pharmacy 2/28/2019 221 FDA Drug Safety Communications re warning about risks and death with combos 8/31/2016 (demonstrative exhibit) 222 T.C.A. § 53-1-101 - Administration short title 223 T.C.A. § 53-11-303 - Factors considered scope 225 T.C.A. § 53-11-308 - Prescriptions 10/1/2013-6/30/2018 226 T.C.A. § 53-11-308 - Prescriptions 7/1/2018-12/31/2018 227 T.C.A. § 53-11-311 - Buprenorphine; prescription requirements; exceptions 7/1/2015-4/11/2018 228 T.C.A. § 53-11-311 - Buprenorphine; prescription requirements; exceptions	213	Business Record Affidavit - Palmetto GBA (DH)	US-001487
216 Declaration of Carl Gainor 2/5/2019 217 Addendum to Declaration of Carl Gainor 3/30/2023 218 Pharmacist Review on Oakley Pharmacy Inc. 2/28/2019 219 Pharmacist Review on Xpress Pharmacy 2/28/2019 220 Overview of Dale Hollow Pharmacy, Xpress Pharmacy, and Anderson Pharmacy 2/28/2019 221 FDA Drug Safety Communications re warning about risks and death with combos 8/31/2016 (demonstrative exhibit) 222 T.C.A. § 53-1-101 - Administration short title 223 T.C.A. § 53-10-110 - Professional judgment of pharmacists' prevention of drug abuse; penalty 224 T.C.A. § 53-11-303 - Factors considered scope 225 T.C.A. § 53-11-308 - Prescriptions 10/1/2013-6/30/2018 226 T.C.A. § 53-11-311 - Buprenorphine; prescription requirements; exceptions 7/1/2015-4/11/2018 227 T.C.A. § 53-11-311 - Buprenorphine; prescription requirements; exceptions 7/1/2015-4/11/2018	214	Business Record Affidavit - Palmetto GBA (DH)	US-001489
217 Addendum to Declaration of Carl Gainor 3/30/2023 218 Pharmacist Review on Oakley Pharmacy Inc. 2/28/2019 219 Pharmacist Review on Xpress Pharmacy 2/28/2019 220 Overview of Dale Hollow Pharmacy, Xpress Pharmacy, and Anderson Pharmacy 2/28/2019 221 FDA Drug Safety Communications re warning about risks and death with combos 8/31/2016 (demonstrative exhibit) 222 T.C.A. § 53-1-101 - Administration short title 223 T.C.A. § 53-10-110 - Professional judgment of pharmacists' prevention of drug abuse; penalty 224 T.C.A. § 53-11-303 - Factors considered scope 225 T.C.A. § 53-11-308 - Prescriptions 10/1/2013-6/30/2018 226 T.C.A. § 53-11-311 - Buprenorphine; prescription requirements; exceptions 7/1/2015-4/11/2018 227 T.C.A. § 53-11-311 - Buprenorphine; prescription requirements; exceptions 7/1/2015-4/11/2018	215	Business Record Affidavit - Palmetto GBA (EFT - DH)	US-001490
Pharmacist Review on Oakley Pharmacy Inc. 2/28/2019 USAO-JP-005165 Pharmacist Review on Xpress Pharmacy 2/28/2019 USAO-JP-005172 Overview of Dale Hollow Pharmacy, Xpress Pharmacy, and Anderson Pharmacy 2/28/2019 FDA Drug Safety Communications re warning about risks and death with combos 8/31/2016 (demonstrative exhibit) T.C.A. § 53-1-101 - Administration short title T.C.A. § 53-10-110 - Professional judgment of pharmacists' prevention of drug abuse; penalty T.C.A. § 53-11-303 - Factors considered scope T.C.A. § 53-11-308 - Prescriptions 10/1/2013-6/30/2018 T.C.A. § 53-11-311 - Buprenorphine; prescription requirements; exceptions 7/1/2015-4/11/2018 T.C.A. § 53-11-311 - Buprenorphine; prescription requirements; exceptions	216	Declaration of Carl Gainor 2/5/2019	USAO-JP-001885
Pharmacist Review on Xpress Pharmacy 2/28/2019 Overview of Dale Hollow Pharmacy, Xpress Pharmacy, and Anderson Pharmacy 2/28/2019 FDA Drug Safety Communications re warning about risks and death with combos 8/31/2016 (demonstrative exhibit) T.C.A. § 53-1-101 - Administration short title T.C.A. § 53-10-110 - Professional judgment of pharmacists' prevention of drug abuse; penalty T.C.A. § 53-11-303 - Factors considered scope T.C.A. § 53-11-308 - Prescriptions 10/1/2013-6/30/2018 T.C.A. § 53-11-311 - Buprenorphine; prescription requirements; exceptions 7/1/2015-4/11/2018 T.C.A. § 53-11-311 - Buprenorphine; prescription requirements; exceptions 7/1/2015-4/11/2018	217	Addendum to Declaration of Carl Gainor 3/30/2023	
220 Overview of Dale Hollow Pharmacy, Xpress Pharmacy, and Anderson Pharmacy 2/28/2019 221 FDA Drug Safety Communications re warning about risks and death with combos 8/31/2016 (demonstrative exhibit) 222 T.C.A. § 53-1-101 - Administration short title 223 T.C.A. § 53-10-110 - Professional judgment of pharmacists' prevention of drug abuse; penalty 224 T.C.A. § 53-11-303 - Factors considered scope 225 T.C.A. § 53-11-308 - Prescriptions 10/1/2013-6/30/2018 226 T.C.A. § 53-11-311 - Buprenorphine; prescription requirements; exceptions 7/1/2015-4/11/2018 228 T.C.A. § 53-11-311 - Buprenorphine; prescription requirements; exceptions	218	Pharmacist Review on Oakley Pharmacy Inc. 2/28/2019	USAO-JP-005165
220 Overview of Dale Hollow Pharmacy, Xpress Pharmacy, and Anderson Pharmacy 2/28/2019 221 FDA Drug Safety Communications re warning about risks and death with combos 8/31/2016 (demonstrative exhibit) 222 T.C.A. § 53-1-101 - Administration short title 223 T.C.A. § 53-10-110 - Professional judgment of pharmacists' prevention of drug abuse; penalty 224 T.C.A. § 53-11-303 - Factors considered scope 225 T.C.A. § 53-11-308 - Prescriptions 10/1/2013-6/30/2018 226 T.C.A. § 53-11-311 - Buprenorphine; prescription requirements; exceptions 7/1/2015-4/11/2018 228 T.C.A. § 53-11-311 - Buprenorphine; prescription requirements; exceptions	219	Pharmacist Review on Xpress Pharmacy 2/28/2019	USAO-JP-005172
FDA Drug Safety Communications re warning about risks and death with combos 8/31/2016 (demonstrative exhibit) T.C.A. § 53-1-101 - Administration short title T.C.A. § 53-10-110 - Professional judgment of pharmacists' prevention of drug abuse; penalty T.C.A. § 53-11-303 - Factors considered scope T.C.A. § 53-11-308 - Prescriptions 10/1/2013-6/30/2018 T.C.A. § 53-11-308 - Prescriptions 7/1/2018-12/31/2018 T.C.A. § 53-11-311 - Buprenorphine; prescription requirements; exceptions 7/1/2015-4/11/2018 T.C.A. § 53-11-311 - Buprenorphine; prescription requirements; exceptions	220		USAO-JP-005166
222 T.C.A. § 53-1-101 - Administration short title 223 T.C.A. § 53-10-110 - Professional judgment of pharmacists' prevention of drug abuse; penalty 224 T.C.A. § 53-11-303 - Factors considered scope 225 T.C.A. § 53-11-308 - Prescriptions 10/1/2013-6/30/2018 226 T.C.A. § 53-11-308 - Prescriptions 7/1/2018-12/31/2018 227 T.C.A. § 53-11-311 - Buprenorphine; prescription requirements; exceptions 7/1/2015-4/11/2018 228 T.C.A. § 53-11-311 - Buprenorphine; prescription requirements; exceptions	221	FDA Drug Safety Communications re warning about risks and death with	
223 T.C.A. § 53-10-110 - Professional judgment of pharmacists' prevention of drug abuse; penalty 224 T.C.A. § 53-11-303 - Factors considered scope 225 T.C.A. § 53-11-308 - Prescriptions 10/1/2013-6/30/2018 226 T.C.A. § 53-11-308 - Prescriptions 7/1/2018-12/31/2018 227 T.C.A. § 53-11-311 - Buprenorphine; prescription requirements; exceptions 7/1/2015-4/11/2018 228 T.C.A. § 53-11-311 - Buprenorphine; prescription requirements; exceptions	222		
224 T.C.A. § 53-11-303 - Factors considered scope 225 T.C.A. § 53-11-308 - Prescriptions 10/1/2013-6/30/2018 226 T.C.A. § 53-11-308 - Prescriptions 7/1/2018-12/31/2018 227 T.C.A. § 53-11-311 - Buprenorphine; prescription requirements; exceptions 7/1/2015-4/11/2018 228 T.C.A. § 53-11-311 - Buprenorphine; prescription requirements; exceptions	223	T.C.A. § 53-10-110 - Professional judgment of pharmacists' prevention of	
225 T.C.A. § 53-11-308 - Prescriptions 10/1/2013-6/30/2018 226 T.C.A. § 53-11-308 - Prescriptions 7/1/2018-12/31/2018 227 T.C.A. § 53-11-311 - Buprenorphine; prescription requirements; exceptions 7/1/2015-4/11/2018 228 T.C.A. § 53-11-311 - Buprenorphine; prescription requirements; exceptions	224		
226 T.C.A. § 53-11-308 - Prescriptions 7/1/2018-12/31/2018 227 T.C.A. § 53-11-311 - Buprenorphine; prescription requirements; exceptions 7/1/2015-4/11/2018 228 T.C.A. § 53-11-311 - Buprenorphine; prescription requirements; exceptions	225	•	
T.C.A. § 53-11-311 - Buprenorphine; prescription requirements; exceptions 7/1/2015-4/11/2018 T.C.A. § 53-11-311 - Buprenorphine; prescription requirements; exceptions	226	•	
T.C.A. § 53-11-311 - Buprenorphine; prescription requirements; exceptions		T.C.A. § 53-11-311 - Buprenorphine; prescription requirements; exceptions	
	228	T.C.A. § 53-11-311 - Buprenorphine; prescription requirements; exceptions	

229	T.C.A. § 53-11-311 - Buprenorphine; prescription requirements; exceptions 7/1/2018-6/30/2020	
230	T.C.A. § 53-11-401 - Offenses; fines and penalties	
231	T.C.A. § 63-10-201 - Short title	
232	T.C.A. § 63-10-203 - Purpose	
233	T.C.A. § 63-10-204 - Definitions 4.2015-5.2015	
234	T.C.A. § 63-10-204 - Definitions 5.2015-6.2016	
235	T.C.A. § 63-10-204 - Definitions 7.2016-6.2017	
236	T.C.A. § 63-10-204 - Definitions 7.2017-6.2018	
237	T.C.A. § 63-10-204 - Definitions 7.2018-4.2022	
238	T.C.A. § 71-5-144 - Medically necessary items and services	
239	Tenn. Comp. R. & Regs. 1140-0101 - Definitions	
240	Tenn. Comp. R. & Regs. 1140-0201 - Pharmacists and pharmacy interns	
241	Tenn. Comp. R. & Regs. 1140-0301 - Responsibilities for pharmaceutical	
2.11	care	
242	Tenn. Comp. R. & Regs. 1140-0303 - Medical and prescription orders	
243	Tenn. Comp. R. & Regs. 1140-0314 - Pharmacists in charge	
244	Tenn. Comp. R. & Regs. 1140-0402 - Personnel	
245	Tenn. Comp. R. & Regs. 1140-0404 - Prescription orders	
246	Tenn. Comp. R. & Regs. 1140-1101 - Definitions	
247	Tenn. Comp. R. & Regs. 1200-13-1301 - Definitions 10.2013-1.2014	
248	Tenn. Comp. R. & Regs. 1200-13-1301 - Definitions 12.2014-3.2015	
249	Tenn. Comp. R. & Regs. 1200-13-1301 - Definitions 6.2016-9.2016	
250	Tenn. Comp. R. & Regs. 1200-13-1301 - Definitions 7.2016-12.2016 (Emergency Regulation)	
251	Tenn. Comp. R. & Regs. 1200-13-1301 - Definitions 9.2016-12.2016	
252	Tenn. Comp. R. & Regs. 1200-13-1301 - Definitions 7.2017-10.2017	
253	Tenn. Comp. R. & Regs. 1200-13-1605 - Medical necessity criteria	
254	42 U.S.C.A. § 1320a-7b - Criminal penalties for acts involving Federal	
25 1	health care programs to 12.2015	
255	42 U.S.C.A. § 1320a-7b - Criminal penalties for acts involving Federal	
276	health care programs 12.2015-2.2018	
256	42 U.S.C.A. § 1320a-7b - Criminal penalties for acts involving Federal health care programs 2.2018-12.2022	
257	42 U.S.C.A. § 1395x - Definitions 10.2014-4.2015	
258	42 U.S.C.A. § 1395x - Definitions 4.2015-6.2015	
259	42 U.S.C.A. § 1395x - Definitions 6.2015-7.2015	
260	42 U.S.C.A. § 1395x - Definitions 7.2015-12.2015	
261	42 U.S.C.A. § 1395x - Definitions 12.2015-12.2016	
262	42 U.S.C.A. § 1395x - Definitions 12.2016-2.2018	
263	42 U.S.C.A. § 1395x - Definitions 2.2018-10.2018	
264	42 U.S.C.A. § 1395x - Definitions 10.2018-3.2020	
265	42 U.S.C.A. § 1395y - Exclusions from coverage and medicare as	
	secondary payer 11.2014-4.2015	
266	42 U.S.C.A. § 1395y - Exclusions from coverage and medicare as	
2.5	secondary payer 4.2015-12.2016	
267	42 U.S.C.A. § 1395y - Exclusions from coverage and medicare as secondary payer 12.2016-10.2018	
	secondary payor 12.2010-10.2010	1

268	42 U.S.C.A. § 1395y - Exclusions from coverage and medicare as	
269	secondary payer 10.2018-12.2020 42 C.F.R. § 411.15 - Particular services excluded from coverage	
270	21 C.F.R. § 1306.04 - Purpose of issue of prescription	
271	21 C.F.R. § 1306.06 - Persons entitled to fill prescriptions	
272	42 C.F.R. § 424.500 - Scope	
	•	
273	42 C.F.R. § 424.505 - Basic enrollment requirement	
274	42 C.F.R. § 424.510 - Requirements for enrolling in the Medicare program	
275	42 C.F.R. § 424.516 - Additional provider and supplier requirements for	
	enrolling and maintaining active enrollment status	
276	in the Medicare program	V
276	TN Board of Pharmacy Compliance Inspection sheet - 1/8/2008	Xpress-000047.20
277	TN Board of Pharmacy Compliance Inspection sheet - Andrea Miller 3/13/2014	Xpress-000025.32
278	TN Board of Pharmacy Compliance Inspection sheet - Andrea Miller 9/16/2016	Xpress-000035.024
279	TN Board of Pharmacy Compliance Inspection sheet - Terry Grinder 11/7/2017	Xpress-000036.16
280	TN Board of Pharmacy Attachments 3 - 5 to Compliance Inspection 11/7/2017 (Grinder) - copies of prescriptions	Xpress-000040.10
281	TN Board of Pharmacy Compliance Inspection sheet - Larry Hill 6/14/2018	Xpress-000049
282	TN Board of Pharmacy 2014000591 - Copy of check to State of TN from Oakley Pharmacy \$260.00 for Consent Order	Xpress-000025.15
283	TN Board of Pharmacy 2016043831 - Attachment 1 to Investigative Report by Andrea Miller 10/26/2016	Xpress-000035.013-014
284	TN Board of Pharmacy 2016043831 - Attachment 2 to Investigative Report 10/26/2016	Xpress-000035.023-024
285	TN Board of Pharmacy 2016043831 - Attachment 3 to Investigative Report 10/26/2016	Xpress-000035.033-039
286	TN Board of Pharmacy 2016043831 - Attachment 5 to Investigative Report 10/26/2016	Xpress-000035.044-045
287	TN BOP 2016043831 - Attachment 9 to Investigative Report 10/26/2016	Xpress-000035.069-072
288	TN BOP 2016043831 - Attachment 10 to Investigative Report 10/26/2016	Xpress-000035.074-075
289	TN BOP 2016043831 - Attachment 11 to Investigative Report 10/26/2016	Xpress-000035.083
290	TN BOP 2018029391 - Attachment 1 to Investigative Report by Terry	Xpress-000035.065 Xpress-000036.15-16
290	Grinder 12/4/2017	Apress-000030.13-10
291	TN Board of Pharmacy 2018029391 - Attachment 9 to Investigative Report 12/4/2017	Xpress-000037.005-006
292	TN Board of Pharmacy 2018029391 - Attachment 10 to Investigative Report 12/4/2017	Xpress-000037.007-010
293	TN Board of Pharmacy 2018029391 - Attachment 11 to Investigative Report 12/4/2017	Xpress-000037.011-017
294	TN Board of Pharmacy 2018029391 - Attachment 16 to Investigative Report 12/4/2027	Xpress-000037.026-027
295	TN Board of Pharmacy 2018029391 - Attachment 17 to Investigative Report 12/4/2017	Xpress-000037.028-029
296	TN Board of Pharmacy 2018029391 - Attachment 18 to Investigative Report 12/4/2017	Xpress-000037.030-031
297	TN Board of Pharmacy 2018029391 - Attachment 19 to Investigative Report 12/4/2017	Xpress-000037.032-034
298	TN Board of Pharmacy 2018029391 - Attachment 20 to Investigative Report 12/4/2017	Xpress-000037.035-037

299	TN Board of Pharmacy 2018029391 - Attachment 21 to Investigative Report 12/4/2017	Xpress-000037.038-040
300	TN Board of Pharmacy 2018029391 - Attachment 22 to Investigative	Xpress-000037.041-043
300	Report 12/4/2017	Apress-000037.041-043
301	TN Board of Pharmacy 2018029391 - Attachment 23 to Investigative	Xpress-000037.044-046
	Report 12/4/2017	
302	TN Board of Pharmacy 2018029391 - Attachment 24 to Investigative Report 12/4/2017	Xpress-000037.047-051
303	TN Board of Pharmacy 2018029391 - Attachment 25 to Investigative	Xpress-000037.052-054
303	Report 12/4/2017	Apress-000057.052-054
304	TN Board of Pharmacy 2018029391 - Attachment 26 to Investigative	Xpress-000037.055-057
	Report 12/4/2017	•
305	TN Board of Pharmacy 2018029391 - Attachment 27 to Investigative	Xpress-000037.058-061
	Report 12/4/2017	
306	TN Board of Pharmacy 2018029391 - Attachment 28 to Investigative	Xpress-000037.062-082
	Report 12/4/2017	
307	TN Board of Pharmacy 2018029391 - Attachment 29 to Investigative	Xpress-000037.083-102
	Report 12/4/2017	•
308	TN Board of Pharmacy 2018029391 - Attachment 33 to Investigative	Xpress-000039.64-65
	Report 12/4/2017	•
309	TN Board of Pharmacy 201802942 - Attachment 3 to report by Larry Hill	Xpress-000049.13-16
	6/14/2018	•
310	TN Board of Pharmacy 201802942 - Attachment 4 to report by Hill	Xpress-000049.17-23
	6/14/2018	
311	TN Board of Pharmacy 201802942 - Attachment 6 to report by Hill	Xpress-000049.29-30
	6/14/2018	1101000 0000 19.29 00
312	TN Board of Pharmacy 201802942 - Attachment 7 to report by Hill	Xpress-000049.31-32
312	6/14/2018	Apress 0000 17.51 32
313	TN Board of Pharmacy 201802942 - Attachment 9 to report by Hill	Xpress-000049.35-37
313	6/14/2018	Apress-0000+7.55-57
314	TN Board of Pharmacy 201802942 - Attachment 10 to report by Hill	Xpress-000049.38-39
311	6/14/2018	Apress 0000 17.30 37
315	TN Board of Pharmacy Attachment 9 to 8/29 & 31/2018 summary report by	Xpress-000050.174-176
	Grinder	-
316	Dale Hollow Pharmacy Team memo by Wendy Smith 2/13/2017	S1-0000014675
317	List of instructions to staff	S1-0000014683
318	Letter to staff with instructions	S1-0000014685
319	Certificate of Completion Combating Medicare Parts C and D FWA - Megan Sever 12/5/2016	S1-0000105989
320	Certificate of Completion Combating Medicare Parts C and D FWA -	S1-0000105991
320	Megan Sever 10/24/2017	51 0000105991
321	TN Department of Health CSMD registration - John Polston 9/9/2016	S1-0000105994
322	Organizational Structure	S1-0000106332
	9	
323	Sign regarding filling of scheduled drugs	S1-0000106342
324	Plan of Action	S1-0000106638
325	Certificate of Completion Combating Medicare Parts C and D FWA - Molly Donaldson 12/5/2016	S1-0000106790
326	Certificate of Completion Combating Medicare Parts C and D FWA -	S1-0000106791
320	Charles Oakley 12/5/2016	51 0000100/71
327	Certificate of Completion Medicare Parts C and D General Compliance	S1-0000106794
	Training - Wanda Marcom 12/5/2016	
328	Certificate of Completion Combating Medicare Parts C and D FWA -	S1-0000106795
	Dorothy Burchett-Forney 12/5/2016	
l		

329	Certificate of Completion Medicare Parts C and D General Compliance Training - Dorothy Burchett-Forney 12/5/2016	S1-0000106796
330	Certificate of Completion Medicare Parts C and D General Compliance Training - Molly Donaldson 12/5/2016	S1-0000106797
331	Certificate of Completion Medicare Parts C and D General Compliance Training - John Polston 11/8/2016	S1-0000106798
332	Certificate of Completion Combating Medicare Parts C and D FWA - Casey Scott 12/5/2016	S1-0000106799
333	Certificate of Completion Medicare Parts C and D General Compliance Training - Casey Scott 12/5/2016	S1-0000106800
334	Certificate of Completion Combating Medicare Parts C and D FWA - Larry Larkin 12/5/2016	S1-0000106801
335	Certificate of Completion Medicare Parts C and D General Compliance Training - Larry Larkin 12/5/2016	S1-0000106802
336	Certificate of Completion Medicare Parts C and D General Compliance Training - Megan Sever 12/5/2016	S1-0000106804
337	Disciplinary Action Report	S1-0000106843
338	Compliance Guide - Donaldson Pharmacy, Inc.	S1-0000121026
339	DMEPOS Train Directory	S1-0000212077
340	Pharmacy Code of Ethics - Donaldson Pharmacy, Inc.	S1-0000212080
341	Pharmacy Personnel spreadsheet	S1-0000212081
342	DMEPOS Accreditation Prep Program Pre-Survey Checklist - Donaldson	S1-0000212082
0.2	Pharmacy, Inc.	21 0000212002
343	DMEPOS Accreditation Policy & Procedures Manual Table of Contents	S1-0000212092
344	Anti-Kickback Violation policy - Donaldson Pharmacy, Inc.	S1-0000212111
345	Pharmacy Code of Ethics Protocol - Donaldson Pharmacy, Inc.	S1-0000212132
346	Rules of the TN Board of Pharmacy Chapter 1140-01 Introductory Rules	S1-0000213029
347	Rules of the TN Board of Pharmacy Chapter 1140-03 Standards of Practice	S1-0000213047
348	MLN Medicare Fraud & Abuse Prevention, Detection, and Reporting Fact Sheet	S1-0000321806
349	APSC Fraud, Waste, & Abuse Policy and Procedure Manual	S1-0000321814
350	Anti-Kickback Violations	S1-0000321827
351	Fraud, Waste and Abuse Compliance Policy	S1-0000321853
352	42 USC 1320a-7b - Criminal Penalties for acts involving Federal health care programs	S1-0000321887
353	Prescription Drug Benefit Manual Chapter 9 - Compliance Program Guidelines and Medicare Managed Care Manual	S1-0000321916
354	Centers for Medicare and Medicaid Services Prescription Drug Benefit Manual Chapter 9 - part D program to control FWA	S1-0000322053
355	Improving Medication Safety In Community Pharmacy: Assessing Risk and Opportunities for Change	S1-0000323472
356	Summary chart - chart of control number, filepath, and custodian	
357	Spreadsheet re Subutex prescriptions	S2-0000011602
358	Dosing Guide - For Optimal Management of Opioid Dependence	S2-0000043285
359	10/14/2016 Letter to physicians from Michael Griffith regarding Subutex prescribing	S2-0000085904
360	List of providers	S2-0000085976
361	"Advertising Numbers" document with provider names and phone numbers	S2-0000085978
362	PAAS National FWA Compliance Program - Policy & Procedure Manual Oct 2013-Oct 2014	S2-0000146272
363	Email to/from Michael Griffith with attached Subutex-Suboxone-Bunavail Advertisement	S2-0000217147

364	7/21/2016 Letter to Larry Larkin from Michael Griffith re early refills	S2-0000227889
365	Certificate of Completion Avoiding Medicare Fraud and Abuse: A Roadmap for Physicians - Michael Griffith 8/1/2016	S2-0000228239
366	Email to/from Tom Weir with attached Board of Pharmacy Compliance Inspections	S2-0000231049
367	Email to Tom Weir from Cathy Cordy re Second Monitoring Report	S2-0000231367
368	Email to Michael Griffith from Kim Stumpf re Amerisource Bergen	S2-0000231867
	questionnaire	
369	Email to Kim Stump from Michael Griffith re buprenorphine dispensing (cc'ing Spivey and Weir)	S2-0000232864
370	BOP Compliance Inspection sheets for 3/13/2014 and 9/30/2014	S2-0000241918
371	6/5/2013 Email to Pam Spivey from James Dougherty (HD Smith) re guidance for a corrective action plan	S2-0000241994
372	6/17/2023 Email to Pam Spivey from James Dougherty (HD Smith) re decreasing cash payment percentages	S2-0000242051
373	5/1/2015 Email to Steve (CCX) from Norma Ehrhart (HD Smith) re late payments	S2-0000242132
374	6/14/2013 Email to Pam Spivey from James Dougherty (HD Smith) re Pharmacy Action Plan 6/14/2013	S2-0000242246
375	5/1/2015 Email to Pam Spivey from Jon Staschiak (Rite Aid) re pharmacy acquisition	S2-0000242253
376	Clay County Express Pharmacy Corrective Action Plan for Controlled Medication Prescriptions	S2-0000242412
377	Preferred IPA of CA Medicare Fraud, Waste, and Abuse Training/General Compliance Training/HIPAA Compliance Training 2014-2015	S2-0000246239
378	CMS Medicare Parts C & D Fraud, Waste, and Abuse Training and General Compliance Training February 2013	S2-0000246468
379	MLN Fraud & Abuse Products	S2-0000246694
380	CMS Medicare Parts C & D Fraud, Waste, and Abuse Training and General Compliance Training February 2013	S2-0000146697
381	Rules of TN Board of Pharmacy Chapter 1140-11 Controlled Substance Monitoring Database	S2-0000247214
382	Rules of TN Board of Pharmacy Chapter 1140-01 Introductory Rules	S2-0000247238
383	Rules of TN Board of Pharmacy Chapter 1140-02 Professional Conduct and	S2-0000247258 S2-0000247268
	Responsibilities	
384	Rules of TN Board of Pharmacy Chapter 1140-03 Standards of Practice	S2-0000247273
385	Anti-Kickback Violation - Clay County Xpress Pharmacy 11/20/2015	S2-0000247519
386	PAAS National Fraud, Waste, and Abuse Compliance/HIPAA Program	S2-0000248077
387	Certificate of Completion (Prime Therapeutics LLC) General Compliance Training - Pam Spivey 10/9/2015	S2-0000248351
388	Certificate of Completion (Prime Therapeutics LLC) Fraud, Waste, and Abuse Training - Patricia Crabtree 10/9/2015	S2-0000248354
389	Certificate of Completion (Prime Therapeutics LLC) General Compliance Training - Patricia Crabtree 10/9/2015	S2-0000248355
390	Certificate of Completion (Prime Therapeutics LLC) Fraud, Waste, and Abuse Training - Larry Larkin 10/17/2015	S2-0000248356
391	Certificate of Completion (Prime Therapeutics LLC) General Compliance Training - Larry Larkin 10/17/2015	S2-0000248357
392	Certificate of Completion (Prime Therapeutics LLC) Fraud, Waste, and	S2-0000248358
393	Abuse Training - Pam Spivey 10/9/2015 Consent Order for Reinstatement - Michael Griffith 4/11/2012	S2-0000248527
394	PAAS National Fraud, Waste, and Abuse Compliance Program - Program	S2-0000248527 S2-0000248637
37 4	Guide Oct 2013-Oct 31, 2014	52-VVVV24803/

395	Pharmacy Attestation of Completed CMS Required Trainings 2/8/2016	S2-0000248926
396	Preferred IPA of CA Medicare Fraud, Waste, and Abuse Training/General Compliance Training/HIPAA Compliance Training 2014-2015	S2-0000360591
397	Flyer referencing Subutex and Suboxone prices	S2-0000361584
398	Flyer referencing Suboxone Films	S2-0000361585
399	Rules of TN Board of Pharmacy Chapter 1140-05 Continuing Education	S2-0000361594
400	Rules of TN Board of Pharmacy Chapter 1140-11 Controlled Substance Monitoring Database	S2-0000361596
401	Rules of TN Board of Pharmacy Chapter 1140-01 Introductory Rules	S2-0000361620
402	Rules of TN Board of Pharmacy Chapter 1140-02 Professional Conduct and Responsibilities	S2-0000361650
403	Rules of TN Board of Pharmacy Chapter 1140-03 Standards of Practice	S2-0000361655
404	Anti-Kickback Violation - Clay County Xpress Pharmacy 11/20/2015	S2-0000362297
405	Agreed Order - Oakley Pharmacy - handwritten notes by Weir	S2-0000362305
406	DEA Memorandum of Agreement	S2-0000362315
407	Consent Order - Griffith 11/27/2011	S2-0000362329
408	TN Board of Pharmacy verification letter regarding history of disciplinary action on license for Michael Griffith 6/18/2018	S2-0000362332
409	Consent Order for Reinstatement - Michael Griffith 4/11/2012	S2-0000362333
410	TN Board of Pharmacy Compliance Inspection sheet 7/24/2017 (Larry Hill)	S2-0000362340
411	Article: Expanding the Pharmacist's Role in Preventing Opioid Abuse: Understanding Abuse-deterrent Formulations and Identifying Risks	S2-0000399637
412	Email to Michael Griffith re completion of 2017 Annual General Compliance and Fraud, Waste, and Abuse Attestation (CVS Caremark)	S2-0000400101
413	Suboxone and Subutex chart	S2-0000403611
414	Letter from Michael Griffith regarding Buprenorphine 6/29/2018	S2-0000403614
415	Monthly dispensing chart	S2-0000403644
416	Suboxone and Subutex chart	S2-0000403645
417	Certificate (PRS) Combating Med. Part C & D Fraud, Waste, and Abuse - Michael Griffith 4/8/2017	S2-0000403664
418	Certificate (PRS) Combating Med. Part C & D Fraud, Waste, and Abuse - Pam Spivey 4/8/2017	S2-0000403667
419	Certificate (PRS) Combating Med. Part C & D Fraud, Waste, and Abuse - Wendy Smith 4/8/2017	S2-0000403676
420	Certificate (PRS) MLN Med. Part C & D General Compliance Training - Wendy Smith 4/8/2017	S2-0000403677
421	Certificate (PRS) MLN Med. Part C & D General Compliance Training - Michael Griffith 4/8/2017	S2-0000403687
422	CPE Monitor Statement - Opioids: Addiction, Overdose Prevention, and Patient Education - Griffith 8/13/2016	S2-0000403692
423	CPE Monitor Statement - Regulatory and Controlled Substance Update - Griffith 2/18/2017	S2-0000403701
424	CPE Monitor Statement - Professional, Legislative and Legal Update - Griffith 2/18/2017	S2-0000403702
425	Summary chart - chart of control number, filepath, and custodian	
426	Prescriptions – J.A. (physical exhibit)	
427	Prescriptions – J.B. (physical exhibit)	
428	Prescriptions – K.C. (physical exhibit)	
429	Prescriptions – K.H. (physical exhibit)	
430	Prescriptions – J.L. (physical exhibit)	
431	Prescriptions – J.L. (physical exhibit)	

432	Prescriptions – P.P. (physical exhibit)	
433	Prescriptions – J.S. (physical exhibit)	
434	Prescriptions – B.S. (physical exhibit)	
435	Prescriptions – R.T. (physical exhibit)	
436	Prescriptions – M.W. (physical exhibit)	
437	Prescription - Count 3 – K.C.; 11/22/2016; Oxycodone	
438	Prescription - Count 4 – P.P.; 2/2/2017; Oxycodone	
439	Prescription - Count 5 – J.B.; 5/3/2018; Oxycodone	
440	Prescription - Count 6 – J.B.; 5/3/2018; Morphine Sulfate	
441-499	INTENTIONALLY LEFT BLANK	
500	Medicare Part D data - Xpress Pharmacy (DISC)	US-002844
501	Medicare Part D data - Dale Hollow Pharmacy (DISC)	US-002845
502	Business record certification - Medicare Part D data	US-002817
503	Medicare Part D data - peer comparison (DISC - 12 files) [ID ONLY]	US-003642
504	Medicare Part D data – J.T. (DISC)	USAO-JP-005160
505	Summary Chart - Xpress Pharmacy Part D PDE Record Summary	
506	Summary Chart - Dale Hollow Pharmacy Part D PDE Record Summary	
507	Summary Chart - Xpress Pharmacy Total Paid and PDE Volume Line	
508	Summary Chart - Dale Hollow Pharmacy Total Paid and PDE Volume Line	
509	Summary Chart - Beneficiary Indictment Count 4 Clay County Xpress	
510	Summary Chart - Beneficiary Indictment Counts 5 and 6 Dale Hollow	
511	Summary Chart - Xpress Pharmacy CII CIV Opioid Beneficiaries Pie Chart	
512	Summary Chart - Dale Hollow Pharmacy CII CIV Opioid Beneficiaries Pie	
312	Chart	
513	Summary Chart - Xpress Pharmacy Mysoline PDE bene	
514	Summary Chart - Dale Hollow Pharmacy Mysoline PDE bene	
515	Summary Chart - Xpress Pharmacy Top Ten Drugs Dispensed by PDE	
	Volume	
516	Summary Chart - Dale Hollow Pharmacy Top Ten Drugs Dispensed by PDE Volume	
517	Summary Chart - Xpress Pharmacy Top Ten CSII CSIV Drugs Dispensed	
017	by PDE Volume	
518	Summary Chart - Dale Hollow Pharmacy Top Ten CSII CSIV Drugs	
	Dispensed by PDE Volume	
519	Summary Chart - Xpress Pharmacy peer comparison Buprenorphine 8mg nationwide	
520	Summary Chart - Xpress Pharmacy peer comparison Buprenorphine 8mg	
320	TN	
521	Summary Chart - Xpress Pharmacy peer comparison Buprenorphine 8mg	
	rural TN	
522	Summary Chart - Xpress Pharmacy peer comparison Buprenorphine all	
523	strengths nationwide Summary Chart - Xpress Pharmacy peer comparison Buprenorphine all	
323	strengths TN	
524	Summary Chart - Xpress Pharmacy peer comparison Buprenorphine all	
	strengths rural TN	
525	Summary Chart - Dale Hollow Pharmacy peer comparison Buprenorphine	
506	8mg nationwide	
526	Summary Chart - Dale Hollow Pharmacy peer comparison Buprenorphine 8mg TN	
	ong m	

527	Summary Chart - Dale Hollow Pharmacy peer comparison Buprenorphine 8mg rural TN	
528	Summary Chart - Dale Hollow Pharmacy peer comparison Buprenorphine all strengths nationwide	
529	Summary Chart - Dale Hollow Pharmacy peer comparison Buprenorphine all strengths TN	
530	Summary Chart - Dale Hollow Pharmacy peer comparison Buprenorphine all strengths rural TN	
531	TennCare data - Clay County Xpress Pharmacy (DISC - 2 files)	US-003079-3080
532	TennCare data - Dale Hollow Pharmacy (DISC - 2 files)	US-003092-3093
533	Business record certification - TennCare data	US-003140
534	Summary Chart - Xpress Pharmacy Claim Line Records	
535	Summary Chart - Xpress Pharmacy Total Billed and Claim Line Volume	
536	Summary Chart - Xpress Pharmacy Patient One Summary of Claim Records	
537	Summary Chart - Xpress Pharmacy Top Ten Drugs by Claim Line Volume	
538	Summary Chart - Xpress Pharmacy Schedule II and IV Top Ten Drugs by Claim Line Volume	
539	Summary Chart - Dale Hollow Pharmacy Claim Line Records	
540	Summary Chart - Dale Hollow Pharmacy Total Billed and Claim Line Volume	
541	Summary Chart - Dale Hollow Pharmacy Top Ten Drugs by Claim Line Volume	
542	Summary Chart - Dale Hollow Pharmacy Schedule II and IV Top Ten Drugs by Claim Line Volume	
543	Summary Chart - Dale Hollow Pharmacy and Xpress Pharmacy Total Claim Line Volume	
544	Summary Chart - Dale Hollow Pharmacy and Xpress Pharmacy Total Billed and Claim Line Volume	
545	CSMD Data - five patients (DISC – 5 files)	US-002851, 2875, 2885, 2902, 2926
546	CSMD Data - Xpress Pharmacy (DISC)	US-002945
547	CSMD Data - Dale Hollow Health Mart (DISC)	US-002946
548	J.B PatientRX History Report	US-002852
549	K.C PatientRX History Report	US-002876
550	P.P PatientRX History Report	US-002886
551	B.S PatientRX History Report	US-002903
552	R.T PatientRX History Report	US-002927
553	Business record certification - CSMD	US-002850
554	Summary chart - Dale Hollow Pharmacy Suboxone v Subutex quantity per month	
555	Summary chart - Xpress Pharmacy Suboxone v Subutex quantity per month	
556	Summary chart - Dale Hollow Pharmacy Suboxone v Subutex prescriptions per month	
557	Summary chart - Xpress Pharmacy Suboxone v Subutex prescriptions per month	
558	Summary chart - Dale Hollow Pharmacy CII and CIV quantity per month	
559	Summary chart - Xpress Pharmacy CII and CIV quantity per month	
560	Summary chart - Dale Hollow Pharmacy and Xpress Pharmacy CII quantity per month	
561	Summary chart - Dale Hollow Pharmacy and Xpress Pharmacy Subutex quantity per month	

562	Summary chart - Dale Hollow Pharmacy and Xpress Pharmacy Subutex	
	quantity per month (combined)	
563	Summary chart - Dale Hollow Pharmacy and Xpress Pharmacy combined	
	drug overlap summary	
564	Summary chart - Dale Hollow Pharmacy Opioid Benzo overlaps with	
	patient totals	
565	Summary chart - Dale Hollow Pharmacy Opioid Benzo overlaps with	
566	patient totals (no patient names)	
566	Summary chart - Dale Hollow Pharmacy Opioid Benzo Muscle Relaxant overlaps with patient totals	
567	Summary chart - Dale Hollow Pharmacy Opioid Benzo Muscle Relaxant	
307	overlaps with patient totals (no patient names)	
568	Summary chart - Xpress Pharmacy Opioid Benzo overlaps with patient	
	totals	
569	Summary chart - Xpress Pharmacy Opioid Benzo overlaps with patient	
	totals (no patient names)	
570	Summary chart - Xpress Pharmacy Opioid Benzo Muscle Relaxant overlaps	
	with patient totals	
571	Summary chart - Xpress Pharmacy Opioid Benzo Muscle Relaxant overlaps	
572	with patient totals (no patient names)	
572	Summary chart - Dale Hollow Pharmacy and Xpress Pharmacy combined opioid benzo overlap with patient totals	
573	Summary chart - Dale Hollow Pharmacy and Xpress Pharmacy combined	
373	opioid benzo overlap with patient totals (no patient names)	
574	Summary chart - Dale Hollow Pharmacy and Xpress Pharmacy combined	
	opioid benzo muscle relaxant overlap with patient totals	
575	Summary chart - Dale Hollow Pharmacy and Xpress Pharmacy combined	
	opioid benzo muscle relaxant overlap with patient totals (no patient names)	
576	DEA ARCOS Data – (DISC - 9 files) [ID ONLY]	US-003641
577	Summary chart - TN Map 2018 purchases of Buprenorphine	
578	Summary chart - TN Map 2017 purchases of Buprenorphine	
579	Summary chart - TN Map 2016 purchases of Buprenorphine	
580	Summary chart - TN Map 2015 purchases of Buprenorphine	
581	Summary chart - TN Map 2014 purchases of Buprenorphine	
582	Summary chart - 2017-2018 Yearly comparisons of Buprenorphine	
302	Products Purchases by Retail Pharmacies	
583	Summary chart - 2014-2016 Yearly comparisons of Buprenorphine	
	Products Purchases by Retail Pharmacies	
584	Summary chart - 2017-2018 Yearly comparisons of Buprenorphine	
	Products w//Naloxone Purchases by Retail Pharmacies	
585	Summary chart - 2014-2016 Yearly comparisons of Buprenorphine	
	Products w//Naloxone Purchases by Retail Pharmacies	
586	Products w//Naloxone Purchases by Retail Pharmacies Summary chart - TN Map 2018 purchases of Oxycodone	
587	Products w//Naloxone Purchases by Retail Pharmacies Summary chart - TN Map 2018 purchases of Oxycodone Summary chart - TN Map 2017 purchases of Oxycodone	
	Products w//Naloxone Purchases by Retail Pharmacies Summary chart - TN Map 2018 purchases of Oxycodone Summary chart - TN Map 2017 purchases of Oxycodone Summary chart - TN Map 2016 purchases of Oxycodone	
587	Products w//Naloxone Purchases by Retail Pharmacies Summary chart - TN Map 2018 purchases of Oxycodone Summary chart - TN Map 2017 purchases of Oxycodone	
587 588	Products w//Naloxone Purchases by Retail Pharmacies Summary chart - TN Map 2018 purchases of Oxycodone Summary chart - TN Map 2017 purchases of Oxycodone Summary chart - TN Map 2016 purchases of Oxycodone	
587 588 589	Products w//Naloxone Purchases by Retail Pharmacies Summary chart - TN Map 2018 purchases of Oxycodone Summary chart - TN Map 2017 purchases of Oxycodone Summary chart - TN Map 2016 purchases of Oxycodone Summary chart - TN Map 2015 purchases of Oxycodone Summary chart - TN Map 2014 purchases of Oxycodone	
587 588 589 590	Products w//Naloxone Purchases by Retail Pharmacies Summary chart - TN Map 2018 purchases of Oxycodone Summary chart - TN Map 2017 purchases of Oxycodone Summary chart - TN Map 2016 purchases of Oxycodone Summary chart - TN Map 2015 purchases of Oxycodone	
587 588 589 590	Products w//Naloxone Purchases by Retail Pharmacies Summary chart - TN Map 2018 purchases of Oxycodone Summary chart - TN Map 2016 purchases of Oxycodone Summary chart - TN Map 2016 purchases of Oxycodone Summary chart - TN Map 2015 purchases of Oxycodone Summary chart - TN Map 2014 purchases of Oxycodone Summary chart - 2017-2018 Yearly comparisons of Oxycodone Purchases by Retail Pharmacies Summary chart - 2014-2016 Yearly comparisons of Oxycodone Purchases	
587 588 589 590 591	Products w//Naloxone Purchases by Retail Pharmacies Summary chart - TN Map 2018 purchases of Oxycodone Summary chart - TN Map 2017 purchases of Oxycodone Summary chart - TN Map 2016 purchases of Oxycodone Summary chart - TN Map 2015 purchases of Oxycodone Summary chart - TN Map 2014 purchases of Oxycodone Summary chart - 2017-2018 Yearly comparisons of Oxycodone Purchases by Retail Pharmacies Summary chart - 2014-2016 Yearly comparisons of Oxycodone Purchases by Retail Pharmacies	
587 588 589 590 591	Products w//Naloxone Purchases by Retail Pharmacies Summary chart - TN Map 2018 purchases of Oxycodone Summary chart - TN Map 2016 purchases of Oxycodone Summary chart - TN Map 2016 purchases of Oxycodone Summary chart - TN Map 2015 purchases of Oxycodone Summary chart - TN Map 2014 purchases of Oxycodone Summary chart - 2017-2018 Yearly comparisons of Oxycodone Purchases by Retail Pharmacies Summary chart - 2014-2016 Yearly comparisons of Oxycodone Purchases	

594	Summary chart - 2014-2018 Suppliers of Remaining Oxycodone Drug Strengths – Dale Hollow Pharmacy	
595	Summary chart - 2014-2018 Monthly Buprenorphine Sales (excluding Nalaxone)	
596	Summary chart - 2014-2018 Monthly Buprenorphine Sales (excluding	
	Nalaxone) - combined Dale Hollow Pharmacy and Xpress Pharmacy	
597	Summary chart - 2014-2018 Monthly Buprenorphine Sales in Dosage Units (excluding Naloxone)	
598	Summary chart - 2014-2018 Quarterly Buprenorphine Sales (excluding Naloxone)	
599	Summary chart - 2014-2018 Quarterly Buprenorphine Sales (excluding Naloxone) - combined Dale Hollow Pharmacy and Xpress Pharmacy	
600	Summary chart - 2014-2018 Quarterly Buprenorphine Sales in Dosage	
	Units (excluding Naloxone)	
601	Summary chart - 2014-2018 Monthly Buprenorphine Sales (with Nalaxone)	
602	Summary chart - 2014-2018 Monthly Buprenorphine Sales (with Nalaxone) - combined Dale Hollow Pharmacy and Xpress Pharmacy	
603	Summary chart - 2014-2018 Monthly Buprenorphine Sales in Dosage Units (with Naloxone)	
604	Summary chart - 2014-2018 Quarterly Buprenorphine Sales (with	
	Naloxone)	
605	Summary chart - 2014-2018 Quarterly Buprenorphine Sales (with	
60.6	Naloxone) - combined Dale Hollow Pharmacy and Xpress Pharmacy	
606	Summary chart - 2014-2018 Quarterly Buprenorphine Sales in Dosage Units (with Naloxone)	
607	Summary chart - 2014-2018 Monthly Oxycodone Sales	
608	Summary chart - 2014-2018 Monthly Oxycodone Sales - combined Dale	
	Hollow Pharmacy and Xpress Pharmacy	
609	Summary chart - 2014-2018 Monthly Oxycodone Sales in Dosage Units	
610	Summary chart - 2014-2018 Quarterly Oxycodone Sales	
611	Summary chart - 2014-2018 Quarterly Oxycodone Sales - combined Dale Hollow Pharmacy and Xpress Pharmacy	
612	Summary chart - 2014-2018 Quarterly Oxycodone Sales in Dosage Units	
613	DEA Most Commonly Abused Controlled Substances	
614	Bank records - all bank accounts (DISC)	
615	Summary chart - Accounts Reviewed	
616	Summary chart - Flow of Funds	
617	Summary chart - Oakley Pharmacy payments to William Donaldson	
618	Summary chart - Garley Harmacy payments to William Donaldson 12/28/2016	
619	Summary chart - Oakley Pharmacy Payment to William Donaldson 3/9/2017	
620	Summary chart - Payments to Kia Motor Finance for 2015 Kia Soul	
621	Summary chart - Cash Deposits to Tom and Vonda Weir Accounts 2014-2019	
622	Summary chart - Cash Deposits: Oakley Pharmacy and Tom and Vonda Weir	
623	Summary chart - Payments to Pamela Spivey 1/2015 to 11/2018	
624	INTENTIONALLY LEFT BLANK	
625	Summary chart - Cash and Insurance Payments to Oakley Pharmacy 4/2014 to 2/2019	
626	Summary chart - Cash and Insurance Payments to Xpress Pharmacy 1/2015	
020	to 11/2018	

627	Summary chart - Cash and Insurance Payments: Xpress Pharmacy	
628	Summary chart - Cash and Insurance Payments: Xpress Pharmacy 1/2015 to 11/2018	
629	Summary chart - Cash and Insurance Payments to Xpress and Oakley Pharmacies 4/2014 to 2/2019	
630	Summary chart - Cash and Insurance Payments: Xpress and Oakley Pharmacies	
631	11/21/2015 Check to Dale Hollow Pharmacy from William Donaldson for copay \$177.00	
632	John Polston phone (physical exhibit) [ID ONLY]	
633	Megan Severe phone (physical exhibit) [ID ONLY]	
634	William Donaldson phone (physical exhibit) [ID ONLY]	
635	Michael Griffith phone (physical exhibit) [ID ONLY]	
636	Device info sheet – William Donaldson phone	
637	Extraction Report - FB messenger chat Donaldson and Amy Short re food stamp card	
638	Extraction Report - SMS Donaldson and Polston re Pam	
639	Extraction Report - IM Donaldson and Amy Short re picking up medicine	
640	Extraction Report - Notes with names	
641	Extraction Report - SMS from Donaldson re fill	
642	Extraction Report - Image of pain clinic search	
643	Extraction Report - Image of Tom Weir contact	
644	Extraction Report - Image of messages between Donaldson and C.K.	
645	Extraction Report - Image of message between Wendy Smith and Donaldson re Tom email address	
646	Extraction Report - Images of Donaldson's comments on FB	
647	Device info sheet – John Polston phone	
648	Extraction Report – V.K. and Polston	
649	Extraction Report - Donaldson, Weir, and Polston	
650	Extraction Report - Donaldson, Smith, and Polston	
651	Extraction Report - Weir, Smith, and Polston	
652	Extraction Report - Molly Donaldson and Polston	
653	Extraction Report - Melissa Ross and Polston	
654	Extraction Report - Smith and Polston	
655	Extraction Report - Weir and Polston	
656	Extraction Report - Donaldson and Polston	
657	Extraction Report - Severe and Polston	
658	Extraction Report - Missy and Polston	
659	Extraction Report - Taylor and Polston	
660	Extraction Report - Smith and Polston SMS	
661	Image of Subutex and Suboxone count 6/28/2016	
662	Image of FB message between patient P.M. and Donaldson re switching pharmacies	
663	Image of Subutex and Suboxone count 7/11/2016	
664	Image of iMessage with Tom Weir re losing customer to Anderson Pharmacy	
665	Image of poster in pharmacy	
666	Image of Dale Hollow on day of vandalism by Donaldson	
667	Image of Dale Hollow on day of vandalism by Donaldson	

668	Image of Dale Hollow on day of vandalism by Donaldson	
669	Device info sheet – Severe phone	
670	Extraction Report - Johnson and Severe	
671	Extraction Report –Smith and Severe	
672	Extraction Report - Severe and Polston	
673	Device info sheet – Michael Griffith phone	
674	Image of interior of Xpress Pharmacy	
675	Image of Carlos the monkey inside of Xpress Pharmacy	
676	Image of interior of Xpress Pharmacy	
677	Image of exterior of Xpress Pharmacy	
678	Image of RX30 screenshot	
679	Image of RX30 screenshot	
680	Image of RX30 screenshot	
681	Image of Buprenorphine/CNS depressants interaction	
682	Image of receipt showing cash in register 8/4/2017	
683	Image of RX30 screenshot	
684	Image of receipt showing cash in register 12/1/2017	
685	Image of RX30 screenshot	
686	Image of receipt showing cash in register 3/21/2018	
687	Image of post-it with written amount \$23,417.22	
688	Image of RX30 screenshot	
689	Image of RX30 screenshot	
690	Image of screenshot Total Ext. Cost \$13,992.31	
691	Image of post-it with written amount \$13,166.99	
692	Image of Donaldson, Smith, and Weir in pharmacy	
693	Image of receipt showing cash in register 7/27/2018	
694	Image of Subutex/Suboxone chart with handwritten notes	
695	Image of Griffith and Spivey New Years 2016 inside Xpress Pharmacy	
696	Image of exterior Xpress Pharmacy	
697	Image of Smith and Weir in pharmacy	
698	Image of B.M. carrying Carlos the monkey inside Xpress Pharmacy	
699	Image of law enforcement outside Xpress Pharmacy	
700	Image of interior Xpress Pharmacy	
701	Image of Carlos the monkey in Xpress Pharmacy	
702	Image of law enforcement outside Xpress Pharmacy	
703	Image of law enforcement outside Xpress Pharmacy	
704	Image of law enforcement outside Xpress Pharmacy	
705	Image of Buprenorphine 8mg sublingual tablets bottle	
706	Image of interior Xpress Pharmacy	
707	Image of Griffith and Spivey in car	
708	Image of "Got Subutex" meme	
709	Image of law enforcement outside Xpress Pharmacy	
710	Image of Tulip Buck	
711	Image of Carlos the monkey in Xpress Pharmacy	
712	Image of interior Xpress Pharmacy - panorama	
713	Image of law enforcement outside Xpress Pharmacy	

714	Image of law enforcement outside Xpress Pharmacy	
715	Image of law enforcement outside Xpress Pharmacy	
716	Image of interior Xpress Pharmacy- medication shelves and Spivey	
717	Image of "RX for 200 Oxycontin" meme	
718	Image of law enforcement outside Xpress Pharmacy	
719	Image of law enforcement outside Xpress Pharmacy	
720	Image of ambulances outside Xpress Pharmacy	
721-724	Intentionally left blank	
725	Summary chart – Dale Hollow Pharmacy and Xpress Pharmacy Number of	
	patients filling multiple opioid products on same fill date	
726	Summary chart – Xpress Pharmacy patients filling multiple opioid products	
	on same day	
727	Summary chart – Dale Hollow Pharmacy patients filling multiple opioid	
720	products on same day	
728	Summary chart – B.S. drug combinations & MME	
729	Summary chart – S.C. drug combinations & MME	
730	Summary chart – Xpress Pharmacy patients filling multiple opioid products	
	from two different doctors on same day	
731	Summary chart – Xpress Pharmacy patients filling multiple opioid products	
722	from two different doctors on same day (no patient names)	
732	Summary chart – Dale Hollow Pharmacy patients filling multiple opioid products from two different doctors on same day	
733	Summary chart – Dale Hollow Pharmacy patients filling multiple opioid	
/33	products from two different doctors on same day (no patient names)	
734	Board of Pharmacy Inspection Dale Hollow, 3/13/2014 (physical exhibit)	
735	2016 AmerisourceBergen statements and account activity, Aug. Sept. and	
,,,,	Oct. 2016 (physical exhibit)	
736	Clay Co. Xpress internal memos re leadership committee, organization	
	structure, and PIC, 12/2/2015 (physical exhibit)	
737	CMS 855s Medicare Enrollment Application, 1/6/2016 (physical exhibit)	
738	Magellan Pharmacy Network Provider Agreement, Oakley Pharmacy/Dale	
	Hollow. 12/12/2018 (physical exhibit)	
739	Xpress Pharmacy of Clay Co. Employee Handbook (physical exhibit)	
740	HD Smith Invoice, Clay Co. Express, 10/7/2015 (physical exhibit)	
741 742	PBA Account Application, Clay Co. Express, 3/31/2015 (physical exhibit) Kentucky Medicaid enrollment, Clay Co. Express (physical exhibit)	
742	Green folder "Buprenorphine Documentation" from Clay Co. Xpress	
773	(physical exhibit)	
744	Tennessee Nonresidential Buprenorphine Treatment Guidelines (physical	
,	exhibit)	
745	Dale Hollow/DEA Memorandum of Agreement – original (physical	
	exhibit)	
746	Handwritten list of findings, red ink, 10/14/2016 (physical exhibit)	
747	AmerisourceBergen invoices, Dale Hollow, May, July, and Aug. 2018	
	(physical exhibit)	
748	Dispensed records on PAAS form, Mar. and April 2015, signed by Polston	
740	(physical exhibit) CH America was Pergen invoices folders May Oct. Dec. 2017 (physical	
749	CII Amerisource Bergen invoices, folders, May, Oct Dec. 2017 (physical exhibit)	
750	Delivery Authorization folder, Dale Hollow (physical exhibit)	
751	Patience Value Profile, S.G. 6/22/2015 (physical exhibit)	
752	G.P. prescription with notes, 10/3/2015 (physical exhibit)	
753	List re S.B., G.G., and J.M. in red marker (physical exhibit)	
	<u> </u>	

754	Dispensed records on PAAS form, 2/9, signed by Polston (physical exhibit)	
755	Records of Bill's deliveries, 10/15/2015 and 10/17/2015 (physical exhibit)	
756	Dale Hollow Pharmacy newspaper advertisement, Dale Hollow HORIZON, 9/30/2015 (physical exhibit)	
757	AmerisourceBergen invoices, Dale Hollow, 1/25/2016 and 2/22/2016 (physical exhibit)	
758	List of medications, released to P. Spivey, 10/5/2015, AmerisourceBergen invoices, Dale Hollow, Dec. 2015 (physical exhibit)	
759	AmerisourceBergen invoices, Dale Hollow, May and June 2016 (physical exhibit)	
760	Black Subutex binder 8/30/16 (physical exhibit)	
761	White Subutex binder, 4/21/16 - 7/20/16, Suboxone films and tabs 4/21/16 - 7/21/16 (physical exhibit)	
762	White binder, Subutex Partials (physical exhibit)	
763	White binder, 6/13/17, Sig. Log (physical exhibit)	

Respectfully submitted,

HENRY C. LEVENTIS United States Attorney Middle District of Tennessee

/s/ Sarah K. Bogni
SARAH K. BOGNI
NANI M. GILKERSON
Assistant United States Attorneys
719 Church Street, Suite 3300
Nashville, Tennessee 37203
Telephone: (615) 736-5151

CERTIFICATE OF SERVICE

I certify that a copy of the foregoing United States' Exhibit List was served on October 30, 2023, via the Court's electronic filing system on all defendants in this matter.

s/Sarah K. Bogni SARAH K. BOGNI Assistant U.S. Attorney